Skip to main content


  • Review
  • Open Access

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature

International Journal of Retina and Vitreous20184:33

  • Received: 15 April 2018
  • Accepted: 12 August 2018
  • Published:



The purpose of this review is to examine the role of eplerenone in the treatment of central serous chorioretinopathy (CSCR).


A comprehensive search of the PubMed database has been conducted regarding eplerenone for CSCR, while studies using spironolactone were excluded. Articles and book chapters cited in the reference lists of articles obtained by this method were reviewed and included when considered appropriate, while the retrieved articles were filtered manually to exclude duplicates.


Oral eplerenone at a dose of 25–50 mg/day has been found to be effective and well-tolerated for the treatment of chronic CSCR. The published studies have shown significant improvement in visual acuity and decrease or total absorption of subretinal fluid in patients with CSCR treated with oral eplerenone. However, it should be noted that the majority of studies were retrospective with limited number of patients and short follow-up. On the other hand, patients presenting widespread retinal pigment epithelium changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention.


CSCR is a challenging disease to understand and treat, since its pathogenesis remains elusive and multifactorial. Pharmacologic approaches, like eplerenone, are intriguing, as they target several pathophysiological pathways and may lead to visual acuity improvement and more rapid recovery.


  • Central serous retinopathy
  • Eplerenone
  • Chronic
  • Mileralocorticoid


Central serous chorioretinopathy (CSCR) is a chorioretinal disease, characterized by serous detachment of the neurosensory retina and/or retinal pigment epithelium (RPE) with consequent accumulation of fluid [13]. In fact, the location and amount of fluid determines the symptomatology in patients with CSCR. If the fluid is located outside the macula, there may be no symptoms, while if the detachment affects the central macula, symptoms may include visual acuity decrease, metamorphopsia, changes in image size, decrease in contrast sensitivity, perception of blind spots or combination of these symptoms [1]. The diagnosis is performed by dilated fundus exam and imaging of the retina and the choroid with optical coherence tomography, fluorescein angiography and indocyanine green angiography [4, 5].

CSCR is a common cause of visual impairment in the working-age population and has been estimated as the fourth most frequently encountered non-surgical retinopathy after age-related macular degeneration, diabetic retinopathy and retinal vein occlusion [13]. It typically affects young to middle-aged men (30–50 years old), but patients with chronic disease (duration more than 6 months) may continue to suffer from the disease even in advanced age [13]. In a population-based study conducted in Minnesota, the reported annual incidence of CSCR was 9.9 per 100,000 male cases compared to 1.7 per 100,000 women [6]. Apart from gender differences, it seems that there is ethnic predilection with Asians presenting higher incidence compared to other ethnic populations [7].

Although the exact pathogenesis of CSCR remains elusive, a number of risk factors for this disorder have been implicated. High levels of endogenous (i.e., in Cushing’s syndrome or in pregnancy) or exogenous (i.e., intra-articular, intranasal, systemic or topical) corticosteroids, type A personality, obstructive sleep apnea, abnormal coagulation and platelet aggregation, infection with Helicobacter pylori, male gender, pregnancy, smoking, hypertension, antibiotic use, alcohol consumption and oxidative stress have been considered to be the most significant risk factors for the development of CSCR [5, 810]. Moreover, genetic susceptibility seems to play an important role in the pathophysiology of CSCR and genetic polymorphisms have been associated with CSCR [1113].

The disease is usually idiopathic and often resolves spontaneously with visual recovery, although occasionally neurosensory retinal detachment persists or relapses and leads to permanent damage of the RPE and photoreceptors with subsequent visual impairment [13]. Current treatment modalities for CSCR generally target the RPE, choroid, or both. They aim to improve the ability of the RPE to remove the subretinal fluid, to diminish leakage from the choroidal vessels, or to decrease fluid flux across the RPE barrier [4, 5]. Management usually involves either waiting for spontaneous resolution, which commonly occurs within 3 months of onset, or the use of focal laser photocoagulation, photodynamic therapy with verteporfin and anti-vascular endothelial growth factor (anti-VEGF) agents in cases of choroidal neovascularization related to CSCR [4]. Recently, mineralocorticoid receptors (MR) have been implicated in the pathophysiology of CSCR; therefore, factors targeting these receptors may be used for the treatment of CSCR [14]. In light of the above, the purpose of this review is to examine the role of eplerenone, an MR antagonist, in the treatment of CSCR.

Literature search

We conducted a comprehensive search of the PubMed database to include articles up to December 31th, 2017, using the following search algorithm: (central serous retinopathy OR central serous chorioretinopathy) AND (eplerenone OR mineralocorticoid). Only studies or cases series evaluating patients with CSCR treated with eplerenone were included in this review, while studies regarding treatment with spironolactone were excluded. Articles and book chapters cited in the reference lists of articles obtained by this method were reviewed and included when considered appropriate, while the retrieved articles were filtered manually to exclude duplicates.

Pathophysiology of CSCR and the “mineralocorticoid receptor” theory

The pathogenesis of CSCR is multifactorial and incompletely understood, making its treatment challenging. The first theory, proposed by Gass, suggested that there is a focal choroidal hyper-permeability, leading to leakage of fluid into the subretinal space [15]. However, Marmor claimed that a focal disruption of the RPE could not cause serous detachment owing to the ability of RPE cells to compensate, and he proposed that CSCR is the result of diffuse metabolic impairment of the RPE [16]. In addition, choroidal ischemia has been shown to be involved in choroidal hyper-permeability and RPE dysfunction [17].

Recently, significant progress has been made on the understanding of the pathogenesis of CSCR, regarding the molecular events triggering choroidal vasodilatation in CSCR. Noticeably, CSCR is the only retinal disease involving fluid accumulation, which is not improved but even worsened by corticosteroids [18]. Corticosteroids include both glucocorticoid (cortisol) and mineralocorticoid (aldosterone), while receptors for glucocorticoid and mineralocorticoid are expressed in Mueller cells and choroidal vessels [18, 19]. Zhao et al. have found that systemic and local glucocorticoids, which are known risk factors for CSCR, act by binding both to the receptor for glucocorticoid and that for mineralocorticoid with equally high affinity [20]. Additionally, Daruich et al. proposed that over activation of the MR in the choroidal endothelial cells induces upregulation of the vasodilator potassium channel KCa2.3, which modulates smooth muscle cells relaxation in the choroidal vasculature [21, 22]. This process has been shown to cause choroidal vasodilation, fluid accumulation in the retina, and to promote retinal neovascularization in hypoxic conditions [18]. Therefore, this link between corticosteroids and CSCR, combined with the observation of an induced CSCR-like model in the rat following MR pathway activation, has prompted the evaluation of MR antagonist in the treatment of CSCR [14].

Eplerenone in the treatment of CSCR

Eplerenone is an MR antagonist with an increased MR selectivity and higher affinity compared to spironolactone. However, eplerenone has about 10- to 20- fold lower binding to progesterone and androgen receptors and does not include the hormonal effects to the same extent, thereby limiting sex-hormone-related adverse side effects [23, 24]. Zhao et al. first reported the treatment of two patients with chronic CSCR using oral eplerenone, presenting rapid subretinal fluid resolution and improvement in visual acuity, which was maintained at 5 months after cessation of treatment [14]. Since then, several studies have investigated the efficacy and safety of eplerenone for CSCR treatment [14, 21, 2538], as it is depicted on Table 1. Summarizing the results of these studies, oral eplerenone at a dose of 25–50 mg/day has been found to be effective and well-tolerated for the treatment of chronic CSCR. There was no significant difference between the two dosages, although it should be noted that the follow-up of the studies is short-term and no randomized study has compared the two treatment regimens [3537]. In addition, the majority of studies were retrospective with limited number of patients [14, 2634]. Sampo et al. conducted a retrospective study with the largest study sample of 27 patients with chronic CSCR and demonstrated statistically significant anatomical and functional improvement in such patients at the 3-month follow-up [34]. Prospective studies have shown similar results [25, 3538]. Only two prospective, randomized studies were published, comparing eplerenone treatment to placebo and showing statistically significant improvement in visual acuity and decrease in subretinal fluid height, as well as central macular thickness, although both of them presented short follow-up time (9 weeks and 6 months respectively) [36, 38]. On the other hand, patients presenting widespread RPE changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention [33]. Apart from studies and case series, two case reports have been published in the literature [39, 40], showing similar results with those of above-mentioned studies. Nevertheless, it has to be mentioned that eplerenone did not influence the hyperfluorescent pattern, which is seen in patients with chronic CSCR on fluorescein angiography and indocyanine green angiography [23].
Table 1

Characteristics and results of studies evaluating oral eplerenone for the treatment of central serous chorioretinopathy


Study design

N eyes

Disease duration

Visual acuity change

Subretinal fluid height change

Central macular thickness change



Schwartz (2017) [38]

Prospective, randomized



Improvement from 0.6 to 0.48 logMAR (p = 0.05)

Improvement from 143.3 to 101.7 μm (p = 0.021)


6 months

Increased CPK

Pichi (2017) [37]

Prospective study



Improvement from 0.2 to 0 logMAR (p = 0.03)

Improvement from 247 to 35 μm (p = 0.004)


2 months

Sedative effect and fatigue

Rahimy (2017) [36]

Prospective, randomized controlled study



Improvement from 0.394 ± 0.28 to 0.330 ± 0.27 logMAR (p = 0.04)

Improvement from 139.3 ± 58.7 to 51.8 ± 52.2 μm (p = 0.02)

Improvement from 366.2 ± 71.1 to 283.7 ± 65.4 μm (p = 0.02)

9 weeks

Dizziness, diarrhea

Gergely (2017) [35]




Improvement from 75.1 to 78.1 letters (p < 0.005)

Improvement from 207 to 120 μm (p < 0.005)

Improvement from 393 to 324 μm

(p < 0.005)

6 months

Dry mouth, dizziness, back pain, somnolence

Sampo (2016) [34]

Retrospective series



Improvement from 0.26 to 0.19 logMAR (p = 0.15)

Decrease of 93.04 μm (p = 0.00018)

Improvement from 371.6 to 294.3 μm

(p = 0.038)

3 months


Cakir (2016) [33]

Retrospective series



Improvement from 0.35 to 0.3 logMAR

Improvement from 117 to 65 μm

Improvement from 342 to 275 μm

3 months

Myotonia, bowel irritation, hyperkaliemia

Kapoor (2016) [32]

Retrospective series



Improvement from 0.55 to 0.32 logMAR (p < 0.05)


Improvement from 324.7 to 259.6 μm

(p < 0.05)

3 months

Fatigue, weight loss, gynecomastia

Ghadiali (2016) [31]

Retrospective series


2 Chronic, 1 Acute

Improvement from 0.67 to 0.75 decimal scale (p = 0.043)


Improvement from 310.3 to 304.7 μm (p = 0.125)

12 months


Leisser (2015) [30]

Retrospective series



Change in visual acuity from 0.48 to 0.71 logMAR


Improvement from 455 to 389 μm

3-38 weeks

Increased liver parameters,

Increased potassium,

Increase bilirubin level

Chin (2015) [29]

Retrospective series



Stability at 20/30 Snellen


Improvement from 387.5 to 352.5 μm


Fatigue, leg cramps,

constipation, dehydration

Salz (2015) [28]

Retrospective series



Improvement from 0.41 to 0.28 logMAR (p = 0.01)

Improvement from 130 to 21 μm (p = 0.004)


3 months


Singh (2015) [27]

Retrospective series



Improvement from 0.42 to 0.29 logMAR (p = 0.024)

Improvement from 131.5 to 46.9 μm (p = 0.002)

Improvement from 339.5 to 270.3 μm (p = 0.029)

6 months


Breukink (2014) [26]

Retrospective series



Improved in 2 patients

Decreased in 2 patients


5 weeks


Bousquet (2013) [25]

Prospective, non-randomized uncontrolled open label study



Improvement from 0.52 ± 0.24 to 0.27 ± 0.19 logMAR (p < 0.001)

Improvement from 175 ± 123 to 36 ± 55 μm (p < 0.01)

Improvement from 352 ± 139 to 189 ± 99 μm (p < 0.01)

3 months

Fatigue, sedative effect

Zhao (2012) [14]

Retrospective series



Improvement from 0.43 to 0.8 decimal scale

Decreased in all eyes


5 months


NA non applicable

Potential adverse events of eplerenone may include hyperkalemia, which can be exaggerated by coexisted renal insufficiency, diabetes mellitus, advanced heart failure, older patient age and interactions with other medications, such as potassium-sparing diuretics, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, fatigue, dizziness, sedative effect, hypertension, diarrhea or constipation, bowel irritation, myotonia, gynecomastia, weight loss and increase of serum liver parameters, bilirubin and CPK levels [2538]. However, adverse events seem to be dose-dependent and are reversible after discontinuation of treatment.

It is worthy to note that since most of the studies examining eplerenone for CSCR treatment are retrospective with short-term follow-up and small sample size, large prospective, randomized studies are needed to scrutinize the role of MR antagonists in CSCR treatment.


CSCR is a challenging disease to understand and treat, since its pathogenesis remains elusive and multifactorial. Systemic emerging pharmacologic approaches, like eplerenone, are intriguing, as they target several pathophysiological pathways and may lead to visual acuity improvement and more rapid recovery. Based on the current literature, eplerenone seems to be efficient, especially at the chronic stage of the disease. Since the results on patients with widespread RPE changes are limited and non-significant, further research is needed to determine which patients are most likely to benefit from eplerenone and their imaging characteristics, while potential combination with other treatment modalities can be also considered.


Authors’ contributions

AV, CD, CV and EG collected data; IC conceived the study and drafted the manuscript; GT and PT supervised the study. All authors critically revised and approved the manuscript. All authors read and approved the final manuscript.


Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data are available upon request.

Consent for publication

Not needed.

Ethics approval and consent to participate

This is a review of the literature and no ethical approval is needed.



Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

2nd Department of Ophthalmology, National and Kapodistrian University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342 Athens, Greece
Medical School, National and Kapodistrian University of Athens, Athens, Greece


  1. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–45.View ArticlePubMedGoogle Scholar
  2. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye. 2010;24:1743–56.View ArticlePubMedGoogle Scholar
  3. Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;12:CD011841.Google Scholar
  4. Quin G, Liew G, Ho IV, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41:187–200.View ArticlePubMedGoogle Scholar
  5. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103–26.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73.View ArticlePubMedGoogle Scholar
  7. How AC, Koh AH. Angiographic characteristics of acute central serous chorioretinopathy in an Asian population. Ann Acad Med Singapore. 2006;35:77–9.PubMedGoogle Scholar
  8. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41:201–14.View ArticlePubMedGoogle Scholar
  9. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Retina. 2012;32(Suppl 1):709.View ArticlePubMedGoogle Scholar
  10. Chatziralli I, Kabanarou SA, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P. Risk Factors for Central Serous Chorioretinopathy: multivariate Approach in a Case-Control Study. Curr Eye Res. 2017;42:1069–73.View ArticlePubMedGoogle Scholar
  11. Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121:1067–72.View ArticlePubMedGoogle Scholar
  12. de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JE, Hoyng CB, den Hollander AI, Boon CJ. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122:562–70.View ArticlePubMedGoogle Scholar
  13. Moschos MM, Gazouli M, Gatzioufas Z, Brouzas D, Nomikarios N, Sivaprasad S, Mitropoulos P, Chatziralli IP. Prevalence of the complement factor H and GSTM1 genes polymorphisms in patients with central serous chorioretinopathy. Retina. 2016;36:402–7.View ArticlePubMedGoogle Scholar
  14. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672–9.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Gass JDM. stereoscopic atlas of macular diseases, 4th ed.; St. Louis, MO: Mosby, 760–763, 1997.Google Scholar
  16. Marmor MF. New hypothesis on the pathogenesis and treatment of serous retinal detachment. Graefe’s Arch Clin Exp Ophthalmol. 1988;226:548–52.View ArticleGoogle Scholar
  17. Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121:26–34.View ArticlePubMedGoogle Scholar
  18. Behar-Cohen F, Zhao M. Corticosteroids and the retina: a role for the mineralocorticoid receptor. Curr Opin Neurol. 2016;29:49–54.View ArticlePubMedGoogle Scholar
  19. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol. 2001;280:181–92.View ArticleGoogle Scholar
  20. Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny JC, Jaisser F, Farman N, Behar-Cohen F. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J. 2010;24:3405–15.View ArticlePubMedGoogle Scholar
  21. Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, Behar-Cohen F. Oral mineralocorticoid-receptor Antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016;5:2.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.View ArticlePubMedGoogle Scholar
  23. Yang D, Eliott D. Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy. Semin Ophthalmol. 2017;32:36–42.View ArticlePubMedGoogle Scholar
  24. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31:1448–55.View ArticlePubMedGoogle Scholar
  25. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33:2096–102.View ArticlePubMedGoogle Scholar
  26. Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92:488–90.View ArticleGoogle Scholar
  27. Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol. 2015;8:310–4.PubMedPubMed CentralGoogle Scholar
  28. Salz DA, Pitcher JD 3rd, Hsu J, Regillo CD, Fineman MS, Elliott KS, Vander JF, Fischer DH, Spirn MJ. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46:439–44.View ArticlePubMedGoogle Scholar
  29. Chin EK, Almeida DR, Roybal CN, Niles PI, Gehrs KM, Sohn EH, Boldt HC, Russell SR, Folk JC. Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol. 2015;9:1449–56.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Leisser C, Hirnschall N, Hackl C, Plasenzotti P, Findl O. Eplerenone in patients with chronic recurring central serous chorioretinopathy. Eur J Ophthalmol. 2016;26:479–84.View ArticlePubMedGoogle Scholar
  31. Ghadiali Q, Jung JJ, Yu S, Patel SN, Yannuzzi LA. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina. 2016;36:611–8.View ArticlePubMedGoogle Scholar
  32. Kapoor KG, Wagner AL. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: a comparative analysis. Ophthalmic Res. 2016;56:17–22.View ArticlePubMedGoogle Scholar
  33. Cakir B, Fischer F, Ehlken C, Bühler A, Stahl A, Schlunck G, Böhringer D, Agostini H, Lange C. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254:2151–7.View ArticlePubMedGoogle Scholar
  34. Sampo M, Soler V, Gascon P, Ho Wang Yin G, Hoffart L, Denis D, Matonti F. Eplerenone treatment in chronic central serous chorioretinopathy. J Fr Ophtalmol. 2016;39:535–42.View ArticlePubMedGoogle Scholar
  35. Gergely R, Kovács I, Schneider M, Resch M, Papp A, Récsán Z, Nagy ZZ, Ecsedy M. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37:1084–91.View ArticlePubMedGoogle Scholar
  36. Rahimy E, Pitcher JD 3rd, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ, Fineman MS. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ECSELSIOR). Retina. 2018;38:962–9.View ArticlePubMedGoogle Scholar
  37. Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P; Central Serous Chorioretinopathy Study Group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol (in press).
  38. Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95:610–8.View ArticleGoogle Scholar
  39. Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. Eur Rev Med Pharmacol Sci. 2013;17:1369–73.PubMedGoogle Scholar
  40. Cioboata M, Alexandrescu C, Hopinca CA, Pienaru MC, Merticariu A, Schmitzer S. A new treatment approach—Eplerenone—in central serous chorioretinopathy—case report. J Med Life. 2016;9:92–4.PubMedPubMed CentralGoogle Scholar


© The Author(s) 2018